GlassScriptPhysician profile
Jorge L Martinez
NPI 1902892714
$1,412.72
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $243.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $229.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $185.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $153.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $149.64 | 2019-2020 | |
| Amarin Pharma, INC. | $117.18 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $96.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.32 | 2019-2020 | |
| Gilead Sciences, INC. | $59.86 | 2019 | |
| Edwards Lifesciences Corporation | $53.50 | 2019-2020 | |
| Vifor Pharma, INC. | $44.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.60 | 2019-2020 | |
| Akcea Therapeutics, INC. | $35.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.09 | 2019 | |
| Pfizer INC. | $26.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.50 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $20.15 | 2019 | |
| Abiomed | $17.83 | 2019 | |
| Grifols USA, LLC | $15.28 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $12.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.